» Articles » PMID: 19506552

Epigenetic Silencing of TTF-1/NKX2-1 Through DNA Hypermethylation and Histone H3 Modulation in Thyroid Carcinomas

Overview
Journal Lab Invest
Specialty Pathology
Date 2009 Jun 10
PMID 19506552
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

Thyroid transcription factor-1 (TTF-1), also known as NKX2-1, is a homeodomain containing transcriptional factor identified in thyroid, lung and central nervous system. In the thyroid, TTF-1 is essential for thyroid organogenesis and governs thyroid functions by regulating various thyroid-specific genes. We previously demonstrated that most differentiated thyroid neoplasms, including follicular adenomas/carcinomas and papillary carcinomas, express TTF-1 at both protein and mRNA levels. However, certain subtypes of thyroid cancers have shown low or negative expression of TTF-1. The aim of our study was to investigate the function of epigenetic modification in dysregulation of TTF-1 in thyroid carcinoma cells. We evaluated the expression of TTF-1 in primary thyroid tissues (normal thyroid, papillary carcinoma and undifferentiated carcinoma) and in thyroid carcinoma cell lines using immunohistochemistry and RT-PCR. Methylation-specific PCR targeting CpG islands of TTF-1 and chromatin immunoprecipitation (ChIP) for histone H3 lysine 9 (H3-lys9) were applied to clarify the correlation of the TTF-1 expression profile and epigenetic status. We also explored whether epigenetic modifiers, including 5-aza-deoxycytidine, could restore TTF-1 expression in thyroid carcinoma cells. In our current study, immunohistochemistry and RT-PCR showed positive expression of TTF-1 in normal thyroids and papillary carcinomas. Meanwhile, most of the undifferentiated carcinomas and the cell lines lost TTF-1 expression. No methylation in the CpG of TTF-1 promoter was detected in normal thyroids or papillary carcinomas. In contrast, DNA methylation was identified in 60% of the undifferentiated carcinomas (6/10) and 50% of the cell lines (4/8). ChIP assay demonstrated that acetylation of H3-lys9 was positively correlated with TTF-1 expression in thyroid carcinoma cells. Finally, DNA demethylating agents could restore TTF-1 gene expression in the thyroid carcinoma cell lines. Our data suggest that epigenetics is involved with inactivation of TTF-1 in thyroid carcinomas, and provide a possible means of using TTF-1 as a target for differentiation-inducing therapy through epigenetic modification.

Citing Articles

Epigenetics in thyroid cancer: a bibliometric analysis.

Li H, Wu P Endocr Connect. 2024; 13(9).

PMID: 38949925 PMC: 11378139. DOI: 10.1530/EC-24-0087.


Organochlorine pesticides and epigenetic alterations in thyroid tumors.

Salimi F, Asadikaram G, Ashrafi M, Zeynali Nejad H, Abolhassani M, Abbasi-Jorjandi M Front Endocrinol (Lausanne). 2023; 14:1130794.

PMID: 37560303 PMC: 10409498. DOI: 10.3389/fendo.2023.1130794.


Epigenetic Targets and Their Inhibitors in Thyroid Cancer Treatment.

Zhang K, Wang J, He Z, Qiu X, Sa R, Chen L Pharmaceuticals (Basel). 2023; 16(4).

PMID: 37111316 PMC: 10142462. DOI: 10.3390/ph16040559.


Reactivated thyroid hormone receptor β attenuates anaplastic thyroid cancer (ATC) stem cell activity.

Zhu X, Zhao L, Doolittle W, Cheng S Endocr Relat Cancer. 2023; 30(6).

PMID: 36939877 PMC: 10354538. DOI: 10.1530/ERC-22-0306.


TTF1 suppresses neuroblastoma growth and induces neuroblastoma differentiation by targeting TrkA and the miR-204/TrkB axis.

Yang T, Li J, Zhuo Z, Zeng H, Tan T, Miao L iScience. 2022; 25(7):104655.

PMID: 35811845 PMC: 9263519. DOI: 10.1016/j.isci.2022.104655.